Abstract | BACKGROUND: OBJECTIVE: METHODS: RESULTS: LIMITATIONS: Case series design with a small number of patients. CONCLUSION: Topical cholesterol/ lovastatin is an effective and well-tolerated therapy for porokeratosis that underscores the utility of a pathogenesis-based therapy that replaces deficient end products and prevents accumulation of potentially toxic precursors.
|
Authors | Lihi Atzmony, Young H Lim, Claire Hamilton, Jonathan S Leventhal, Annette Wagner, Amy S Paller, Keith A Choate |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 82
Issue 1
Pg. 123-131
(Jan 2020)
ISSN: 1097-6787 [Electronic] United States |
PMID | 31449901
(Publication Type: Journal Article)
|
Copyright | Copyright © 2019. Published by Elsevier Inc. |
Chemical References |
- Anticholesteremic Agents
- Drug Combinations
- Ointments
- Cholesterol
- Lovastatin
- Phosphotransferases (Phosphate Group Acceptor)
- phosphomevalonate kinase
- Carboxy-Lyases
- pyrophosphomevalonate decarboxylase
|
Topics |
- Administration, Cutaneous
- Adult
- Anticholesteremic Agents
(administration & dosage)
- Carboxy-Lyases
(genetics)
- Child, Preschool
- Cholesterol
(administration & dosage)
- Drug Combinations
- Genotype
- Humans
- Lovastatin
(administration & dosage)
- Middle Aged
- Mutation
- Ointments
- Phosphotransferases (Phosphate Group Acceptor)
(genetics)
- Porokeratosis
(drug therapy, genetics)
- Young Adult
|